<p>德康醫療（NASDAQ: DXCM）在過去三個月內被 7 位分析師分析，顯示出從看漲到看跌的多樣化觀點。</p>
<p>下表總結了他們最近的評級，展示了過去 30 天內情緒的變化，並與前幾個月進行比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師為德康醫療設定了 12 個月的價格目標，顯示出平均目標為 77.14 美元，最高預估為 86.00 美元，最低預估為 68.00 美元。當前平均價格目標較之前的 77.00 美元上升了 0.18%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png"/></p>
<h2>分析師評級解析：詳細審查</h2>
<p>通過審查最近的分析師行動，我們可以洞察金融專家如何看待德康醫療。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>低於大盤</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上調</td>
<td>超過大盤</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上調</td>
<td>超過大盤</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>上調</td>
<td>買入</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>超配</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>宣佈</td>
<td>持平</td>
<td>$68.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>關鍵洞察：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現的變化頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對德康醫療近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師提供的定性見解揭示了股票表現，從 “超過大盤” 到 “低於大盤”。這些評級傳達了德康醫療相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供德康醫療未來價值的估計。檢查當前和之前的目標提供了分析師預期變化的洞察。</li>
</ul>
<p>為了獲取德康醫療市場表現的有價值見解，請考慮將這些分析師評估與關鍵財務指標結合使用。保持信息靈通，做出明智的決策，使用我們的評級表。</p>
<p>隨時瞭解德康醫療的分析師評級。</p>
<h2>關於德康醫療</h2>
<p>德康醫療設計並商業化用於糖尿病患者的連續血糖監測系統。CGM 系統作為傳統血糖儀過程的替代方案，公司正在發展其 CGM 系統，以便與 Insulet 和 Tandem 的胰島素泵集成，實現自動胰島素輸送。德康醫療的 CGM 通過醫療設備分銷商以及零售藥店提供。</p>
<h3>財務洞察：德康醫療</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業基準，面臨規模限制。這可能受到增長預期或運營能力等因素的影響。</p>
<p><strong>收入增長：</strong> 德康醫療在第三季度的表現顯著。截至 2025 年 9 月 30 日，公司實現了 <strong>21.64%</strong> 的令人印象深刻的收入增長率。這標誌着公司頂線收益的顯著增加。與同行相比，公司實現的增長率高於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> 德康醫療的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。公司展現出強大的盈利能力和有效的成本管理，淨利潤率達到 <strong>23.47%</strong>。</p>
<p><strong>股本回報率（ROE）：</strong> 德康醫療的 ROE 超越行業基準，達到 <strong>10.71%</strong>。這標誌着強大的財務管理和有效利用股東權益資本。</p>
<p><strong>資產回報率（ROA）：</strong> 德康醫療的 ROA 超過行業標準，突顯了公司的卓越財務表現。ROA 達到 <strong>3.83%</strong>，公司有效利用其資產以獲得最佳回報。</p>
<p><strong>債務管理：</strong> 德康醫療的債務與股本比率超過行業規範，達到 <strong>0.94</strong>。這表明公司承擔了相當數量的債務，可能面臨財務挑戰。</p>
<h2>分析師評級：簡化版</h2>
<p>分析師評級作為股票表現的重要指標，由銀行和金融系統的專家提供。這些專家認真分析公司財務報表，參與電話會議，並與內部人士交流，以生成個別股票的季度評級。</p>
<p>一些分析師還會提供增長預期、收益和收入等指標的預測，以進一步指導股票。使用分析師評級的投資者應注意，這些專業建議來自人類，可能會出現錯誤。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

德康醫療

標普健康醫療設備 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

美國醫藥設備 ETF - iShares

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

<p>德康醫療（NASDAQ:DXCM）在過去三個月內獲得了 7 位分析師的混合評級，12 個月的平均目標價為 77.14 美元。最近的評估顯示出不同的情緒，一些分析師維持或提高了他們的評級，而另一些則降低了評級。關鍵見解包括 21.64% 的收入增長率和 23.47% 的淨利潤率。然而，該公司的債務與股本比率為 0.94，表明其債務相對較高。分析師的評級對投資者至關重要，反映了專家對股票表現和未來預期的看法</p>

<p>DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>德康醫療（NASDAQ: DXCM）在過去三個月內被 7 位分析師分析，顯示出從看漲到看跌的多樣化觀點。</p>
</div><p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表總結了他們最近的評級，展示了過去 30 天內情緒的變化，並與前幾個月進行比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for DexCom, revealing an average target of $77.14, a high estimate of $86.00, and a low estimate of $68.00. Surpassing the previous average price target of $77.00, the current average has increased by 0.18%.</p>
<div class="lb-trans"><p>分析師為德康醫療設定了 12 個月的價格目標，顯示出平均目標為 77.14 美元，最高預估為 86.00 美元，最低預估為 68.00 美元。當前平均價格目標較之前的 77.00 美元上升了 0.18%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770984062_0.png"/></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<div class="lb-trans"><h2>分析師評級解析：詳細審查</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive DexCom. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過審查最近的分析師行動，我們可以洞察金融專家如何看待德康醫療。以下總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$68.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>低於大盤</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上調</td>
<td>超過大盤</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上調</td>
<td>超過大盤</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>上調</td>
<td>買入</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>超配</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>宣佈</td>
<td>持平</td>
<td>$68.00</td>
<td>-</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for DexCom's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現的變化頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對德康醫療近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師提供的定性見解揭示了股票表現，從 “超過大盤” 到 “低於大盤”。這些評級傳達了德康醫療相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供德康醫療未來價值的估計。檢查當前和之前的目標提供了分析師預期變化的洞察。</li>
</ul>
</div><p>For valuable insights into DexCom's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了獲取德康醫療市場表現的有價值見解，請考慮將這些分析師評估與關鍵財務指標結合使用。保持信息靈通，做出明智的決策，使用我們的評級表。</p>
</div><p>Stay up to date on DexCom analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解德康醫療的分析師評級。</p>
</div><h2>About DexCom</h2>
<div class="lb-trans"><h2>關於德康醫療</h2>
</div><p>DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.</p>
<div class="lb-trans"><p>德康醫療設計並商業化用於糖尿病患者的連續血糖監測系統。CGM 系統作為傳統血糖儀過程的替代方案，公司正在發展其 CGM 系統，以便與 Insulet 和 Tandem 的胰島素泵集成，實現自動胰島素輸送。德康醫療的 CGM 通過醫療設備分銷商以及零售藥店提供。</p>
</div><h3>Financial Insights: DexCom</h3>
<div class="lb-trans"><h3>財務洞察：德康醫療</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業基準，面臨規模限制。這可能受到增長預期或運營能力等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> DexCom's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>21.64%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> 德康醫療在第三季度的表現顯著。截至 2025 年 9 月 30 日，公司實現了 <strong>21.64%</strong> 的令人印象深刻的收入增長率。這標誌着公司頂線收益的顯著增加。與同行相比，公司實現的增長率高於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.47%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 德康醫療的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。公司展現出強大的盈利能力和有效的成本管理，淨利潤率達到 <strong>23.47%</strong>。</p>
</div><p><strong>Return on Equity (ROE):</strong> DexCom's ROE excels beyond industry benchmarks, reaching <strong>10.71%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 德康醫療的 ROE 超越行業基準，達到 <strong>10.71%</strong>。這標誌着強大的財務管理和有效利用股東權益資本。</p>
</div><p><strong>Return on Assets (ROA):</strong> DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.83%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 德康醫療的 ROA 超過行業標準，突顯了公司的卓越財務表現。ROA 達到 <strong>3.83%</strong>，公司有效利用其資產以獲得最佳回報。</p>
</div><p><strong>Debt Management:</strong> DexCom's debt-to-equity ratio surpasses industry norms, standing at <strong>0.94</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 德康醫療的債務與股本比率超過行業規範，達到 <strong>0.94</strong>。這表明公司承擔了相當數量的債務，可能面臨財務挑戰。</p>
</div><h2>Analyst Ratings: Simplified</h2>
<div class="lb-trans"><h2>分析師評級：簡化版</h2>
</div><p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<div class="lb-trans"><p>分析師評級作為股票表現的重要指標，由銀行和金融系統的專家提供。這些專家認真分析公司財務報表，參與電話會議，並與內部人士交流，以生成個別股票的季度評級。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析師還會提供增長預期、收益和收入等指標的預測，以進一步指導股票。使用分析師評級的投資者應注意，這些專業建議來自人類，可能會出現錯誤。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

7 Analysts Have This To Say About DexCom

benzinga_article

7 位分析師對 DexCom 的看法